Precision BioSciences, Inc. announced on August 6, 2025, positive Phase 1 safety and efficacy data for Cohort 1 of its ELIMINATE-B trial for PBGENE-HBV, its lead program for chronic Hepatitis B. The data, as of July 28, 2025, established proof-of-activity for PBGENE-HBV, the first clinical modality designed to eliminate cccDNA and inactivate integrated HBV DNA.
Cohort 1, dosed at 0.2 mg/kg, demonstrated a safe and well-tolerated profile across multiple dose administrations for all three patients, with no Grade 2 or higher treatment-related adverse events, serious adverse events, or dose-limiting toxicities. All three patients showed substantial HBsAg reduction, with best responses ranging from 47% to 69% compared to baseline.
Notably, one of the three patients achieved a durable HBsAg reduction of approximately 50% from baseline, maintained seven months after the initial dose administration. Initial safety data from Cohort 2 (0.4 mg/kg) also showed a favorable safety profile, leading the Data Monitoring Committee to endorse the initiation of Cohort 3.
In conjunction with the clinical updates, Precision BioSciences announced an extension of its expected cash runway into the second half of 2027. This extension, achieved through an operating efficiency program initiated in July 2025, is expected to reduce annual cash operating expenses by approximately $25 million in both 2026 and 2027, providing more than two years of operating cash to support advancement of its lead programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.